Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.

Yasuhiro, Tomoko

Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab. [electronic resource] - Leukemia & lymphoma 03 2017 - 699-707 p. digital

Publication Type: Journal Article

1029-2403

10.1080/10428194.2016.1201567 doi


Agammaglobulinaemia Tyrosine Kinase
Animals
Antibodies, Monoclonal, Humanized--administration & dosage
Cell Line, Tumor
Cytotoxicity, Immunologic--drug effects
Disease Models, Animal
Drug Therapy, Combination
Female
Humans
Imidazoles--administration & dosage
Killer Cells, Natural--drug effects
Lymphoma, Large B-Cell, Diffuse--drug therapy
Mice
Neoplasm Staging
Protein Kinase Inhibitors--pharmacology
Protein-Tyrosine Kinases--antagonists & inhibitors
Pyrimidines--administration & dosage
Rituximab--administration & dosage
Treatment Outcome
Tumor Burden--drug effects
Xenograft Model Antitumor Assays